M Bednaříková, J Hausnerová, L Minář, R Taslerová, P Vinklerová, L Ehrlichová, J Trizuljak, I Blaháková, D Princ, K Matulová, P Ovesná, O Slabý, V Weinberger
BACKGROUND: Molecular classification has brought significant changes in the management of endometrial cancer (EC). In this article, we aim to analyze our first experience with an implementation of molecular testing into daily clinical practice. MATERIALS AND METHODS: In all newly diagnosed EC, the status of mismatch repair (MMR) and p53 proteins has been evaluated immunohistochemically as a part of the routine histopathological examination since May 2021. In tumors that do not meet clinical criteria for a low risk and those with MMR deficiency or p53 mutation, the molecular genetic testing of the POLE gene is performed as well...
2023: Klinická Onkologie: Casopis Ceské a Slovenské Onkologické Spolecnosti